1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
H. Lundbeck A/S

H. Lundbeck A/S

HLUBF
H. Lundbeck A/SUS flagOther OTC
5.94
USD
+0.22
- -
6.31BMarket Cap
H. Lundbeck A/S
HLUBF
(Other OTC)

Recent

price

5.94

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
75.29
81.63
75.47
77.79
68.63
74.28
79.29
87.52
89.97
87.36
88.92
16.41
18.38
20.07
22.19
24.83
25.69
Revenue per Share
12.57
11.64
5.94
4.36
-0.78
-28.98
6.14
13.29
19.67
11.64
7.96
1.33
1.93
2.31
3.17
3.22
3.72
Basic EPS, GAAP
12.43
10.26
2.36
11.45
0.31
-14.04
14.12
16.81
26.56
10.9
16.9
1.67
2.72
3.61
2.78
4.9
5.48
Free Cash Flow per Basic Share
3.07
3.77
3.49
2
2.77
- -
- -
2.45
8
12
4.1
0.5
0.4
0.58
0.7
0.95
1.15
Dividend per Share
57.02
64.94
67.2
69.72
65.63
37.07
44.42
56.53
67.97
80.4
84.26
17.69
19.32
21.04
23.53
25.81
26.25
Book Value per Share
15.86
22.09
21.26
22.45
4.36
-5.14
4.34
23.37
31.35
-47.68
-29.01
-4.5
-1.73
1.36
-16.16
-10.96
-10.57
Tangible Book Value per Share
196
196
196
196
196
196
197
198
199
199
199
993
993
992
991
992
993
Basic Weighted Avg Shares
14,765
16,007
14,802
15,258
13,468
14,594
15,634
17,286
17,875
17,358
17,672
16,299
18,246
19,912
22,004
24,630
25,520
Sales/Revenue/Turnover
22.74
21.2
11.66
10.48
0.74
-46.7
14.66
25.8
28.3
20.02
11.26
12.33
15.63
16.05
14.86
21.42
22.46
Operating Margin (%)
1,036
1,235
888
- -
1,453
7,026
1,554
- -
- -
1,670
2,793
1,710
1,811
2,012
1,876
1,865
- -
Depreciation Expense
2,466
2,282
1,165
855
-153
-5,694
1,211
2,624
3,907
2,313
1,581
1,318
1,916
2,290
3,143
3,192
3,698
Net Income, GAAP
25.02
30.79
29.86
41.92
- -
- -
43.86
38.65
26.13
23.56
17.05
16.64
22.55
23.49
15.49
28.86
28
Effective Tax Rate (%)
16.7
14.26
7.87
5.6
-1.14
-39.02
7.75
15.18
21.86
13.33
8.95
8.09
10.5
11.5
14.28
12.96
14.49
Profit Margin (%)
2,709
4,107
4,200
4,845
2,184
-88
-252
2,365
4,073
-1,242
93
-206
3,213
5,299
4,430
3,930
3,656
Working Capital
1,918
1,907
1,890
2,141
3,259
3,687
1,708
57
- -
7,499
5,813
5,236
5,491
4,065
16,611
11,580
10,854
LT Debt
11,122
12,776
13,198
13,481
13,526
8,785
9,694
12,181
14,251
16,782
16,973
18,279
20,779
22,045
25,010
24,903
25,626
Total Equity
19.72
16.84
8.1
6.04
- -
- -
10.6
22.82
28.14
12.9
6.3
6.76
8.67
9.12
8.04
9.48
10.75
Return on Invested Capital (%)
20.21
16.87
8.86
6.59
- -
- -
12.74
25.75
31.6
12.09
6.9
6.08
8.38
9.36
9.96
9.21
9.77
Return on Capital (%)
24.04
19.08
8.99
6.37
-1.15
-56.48
15.1
26.34
31.68
15.69
9.66
7.68
10.43
11.43
14.22
13.04
14.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
76
74
74
LT Borrowings
11,924
11,185
10,446
LT Finance Leases
408
395
408
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
992
992
992
Market Capitalization
34,649
33,867
31,051

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13,359
12,783
12,647
Cash, Cash Equivalents & STI
3,479
3,433
1,956
Accounts Receivable, Net
5,609
3,605
6,092
Inventories
4,271
4,473
4,599
Total Current Liabilities
9,104
8,853
8,991
Payables & Accruals
- -
- -
- -
ST Debt
76
74
74
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.24%
8.1%
-0.43%
Free Cash Flow
-2.87%
19.58%
76.13%
Net Income, GAAP
5.89%
17.41%
1.56%
Sales/Revenue/Turnover
5.58%
7.15%
11.93%
Total Cash Common Dividend
- -
8.46%
35.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,288
5,453
5,722
5,541
22,004
2025
6,235
6,023
6,279
6,093
24,630
2026
7,125
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.01
0.78
0.78
- -
3.17
2025
1.13
0.97
1.11
- -
3.22
2026
1.67
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
0.7
2025
0.95
- -
- -
- -
0.95
2026
1.15
- -
- -
- -
- -
Similar Companies
Cyclo Therapeutics, Inc. (CYTHW)
Anything Technologies Media, Inc. (EXMT)
Mangalam Drugs & Organics Limited (MANGALAM.BO)
Dr. Reddy's Laboratories Limited (DRREDDY.BO)
Gabather AB (publ) (GABA.ST)
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)
Business
H. Lundbeck A/S is a Denmark-based international pharmaceutical company specializing in the research, development, manufacturing, marketing, and sale of innovative therapies for brain diseases, including psychiatric and neurological disorders such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, migraine, and alcohol dependence. Founded in 1915 and headquartered in Valby, Copenhagen, the company operates in more than 50 countries with production facilities in Denmark, France, and Italy, and research centers in Denmark and the United States; its products are registered in over 80 countries worldwide. Lundbeck's core portfolio encompasses strategic brands including Rexulti/Rxulti (brexpiprazole) for depression, anxiety, and psychosis; Brintellix/Trintellix (vortioxetine) for depression; Abilify Maintena (aripiprazole) for psychosis; Vyepti (eptinezumab) for migraine prevention; Cipralex/Lexapro (escitalopram) and Cipramil (citalopram) for depression and anxiety; Ebixa (memantine) for Alzheimer's disease; Azilect (rasagiline) for Parkinson's disease; Northera (droxidopa) for neurogenic orthostatic hypotension; Sabril (vigabatrin), Onfi/Frisium (clobazam) for epilepsy; Selincro (nalmefene) for alcohol dependence; and mature antipsychotics such as Serdolect (sertindole), Clopixol/Cisordinol (zuclopenthixol), Fluanxol (flupentixol), and Truxal (chlorprothixene).[image:1 from products page] In recent developments, Lundbeck acquired Longboard Pharmaceuticals in 2024 for approximately $2.5 billion to add bexicaserin, a 5-HT2C agonist in development for developmental and epileptic encephalopathies including Dravet and Lennox-Gastaut syndromes; partnered with Iambic Therapeutics in 2024 to leverage AI-driven drug discovery for neurological diseases; and in September 2025 announced partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals to transition sales, marketing, access, and distribution in 27 markets across Europe and International Operations by December 2025, sharpening commercial focus on neuro-rare and neuro-specialty franchises while incurring one-off costs of DKK 390 million.